No single test is diagnostic of Crohn's disease (CD). In the presence of a compatible clinical presentation, diagnosis is by convention confirmed by a combination of imaging, serologic, endoscopic and histologic investigations. This diagnostic recommendation should be maintained, even though histology is often ‘compatible with' rather than ‘diagnostic of' suspected CD. The importance of histology varies depending on the specific sites of macroscopic disease. Histology is particularly important in distinguishing type of inflammatory bowel disease, when the colon predominantly is involved, and in confirming CD when macroscopic disease is atypically located.

Keywords:
Crohn’s disease, Diagnosis, Histology
1.
Baumgart DC, Sandborn WJ: Crohn's disease. Lancet 2012;380:1590-1605.
2.
Van Assche G, Dignass A, Panes J, Beaugerie L, Karagiannis J, Allez M, et al: The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. J Crohns Colitis 2010;4:7-27.
3.
Stange EF, Travis SP, Vermeire S, Reinisch W, Geboes K, Barakauskiene A, et al: European evidence-based Consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohns Colitis 2008;2:1-23.
4.
Rubio CA, Orrego A, Nesi G, Finkel Y: Frequency of epithelioid granulomas in colonoscopic biopsy specimens from paediatric and adult patients with Crohn's colitis. J Clin Pathol 2007;60:1268-1272.
5.
Silverberg MS, Satsangi J, Ahmad T, et al: Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005;19(suppl A):5-36.
6.
Levine A, Griffiths A, Markowitz J, Wilson DC, Turner D, Russell RK, et al: Pediatric modification of the Montreal Classification of Inflammatory Bowel Disease: The Paris classification. Inflamm Bowel Dis 2011;17:1314-1321.
7.
Geboes K, Van Eyken P: Inflammatory bowel disease unclassified and indeterminate colitis: the role of the pathologist. J Clin Pathol 2009;62; 201-205.
8.
Bousvaros A, Antonioli DA, Colletti RB, Dubinsky MC, Glickman JN, Gold BD, et al: Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America. J Pediatr Gastroenterol Nutr 2007;44:653-674.
9.
Goldstein N, Dulai M: Contemporary morphologic definition of backwash ileitis in ulcerative colitis and features that distinguish it from Crohn disease. Am J Clin Pathol 2006;126:365-376.
10.
Haskell H, Andrews CW Jr, Reddy SI, Dendrinos K, Farraye FA, Stucchi AF, et al: Pathologic features and clinical significance of ‘backwash' ileitis in ulcerative colitis. Am J Surg Pathol 2005;29:1472-1481.
11.
Perisic VN, Filipovic D: Ileoscopy and its clinical role in the assessment of backwash ileitis in children with ulcerative pancolitis: Belgrade experience. J Pediatr Gastroenterol Nutr 1988;7:146-148.
12.
de Bie CI, Buderus S, Sandhu BK, de RL, Paerregaard A, Veres G, et al: Diagnostic workup of paediatric patients with inflammatory bowel disease in Europe: results of a 5-year audit of the EUROKIDS Registry. J Pediatr Gastroenterol Nutr 2012;54:374-380.
13.
Kundhal P, Stormon M, Zachos M, et al: Gastric antral biopsy in the differentiation of pediatric colitides. Am J Gastroenterol 2003;98:557-561.
14.
Paerregaard A: What does the IBD patient hide in the upper gastrointestinal tract? Inflamm Bowel Dis 2009;15:1101-1104.
15.
Glickman JN, Bousvaros A, Farraye FA, Zholudev A, Friedman S, Wang HH, et al: Pediatric patients with untreated ulcerative colitis may present initially with unusual morphologic findings. Am J Surg Pathol 2004;28:190-197.
16.
Rajwal SR, Puntis JW, McClean P, et al: Endoscopic rectal sparing in children with untreated ulcerative colitis. J Pediatr Gastroenterol Nutr 2004;38:66-69.
17.
Levine A, de Bie CL, Turner D, et al: Atypical disease phenotypes in paediatric ulcerative colitis: 5-year analyses of the EUROKIDS registry. Inflamm Bowel Dis, DOI: 10.1002/ibd.23013.
18.
Sherlock ME, Tomlinson G, Walters T, Urbach D, Griffiths AM: Paediatric IBD - how reliably does the Montreal classification perform? J Crohn Colitis 2011:5:S145.
19.
Quinton JF, Sendid B, Reumaux D, et al: Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 1998;42:788-791.
20.
Jostens L, Ripke S, Weersma R, et al: Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012;491:119-124.
21.
Davis MK, Andres JM, Jolley CD, Novak DA, Haafiz AB, González-Peralta RP: Antibodies to Escherichia coli outer membrane porin C in the absence of anti-Saccharomyces cerevisiae antibodies and anti-neutrophil cytoplasmic antibodies are an unreliable marker of Crohn disease and ulcerative colitis. J Pediatr Gastroenterol Nutr 2007;45:409-413.
22.
Ashorn S, Honkanen T, Kolho KL, Ashorn M, Välineva T, Wei B, Braun J, Rantala I, Luukkaala T, Iltanen S: Fecal calprotectin levels and serological responses to microbial antigens among children and adolescents with inflammatory bowel disease. Inflamm Bowel Dis 2009;15:199-205.
23.
Joossens S, Reinisch W, Vermeire S, et al: The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology 2002;122:1242-1247.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.